Skip to Main Content
CWRU Links

2011 Articles

March 28, 2011

Date Released: 28 March 2011
News Banner


NCI Cooperative Group Reorganization

There has been intense interest in discussion over efforts of the National Cancer Institute to re-organize cooperative groups. This affects all of us in the Cancer Center because it will alter the way we conduct early translational and clinical trial research with cancer patients.

At the February 2011 cancer directors retreat, a number of issues came forward regarding the intentions of the National Cancer Institute in this effort. As a result, a formal committee was put together with a number of cancer center directors and created a proposal: Building an Integrated National Cancer Clinical Trials Program: A Proposal for Re-Organization from NCI Cancer Center Directors. In addition, we at the Case Comprehensive Cancer Center met to discuss our approach and comments about the trial's efforts amongst the cooperative groups, and prepared a response: Case CCC Cooperative Group White Paper.

There is ongoing dialogue about these restructuring efforts, and I would like our members to be well-informed. I will be participating in a discussion at the AACR Annual Meeting, and value receiving your comments before April 2.

Stan Gerson, MD
Director, Case Comprehensive Cancer Center


Ruth Keri PhD, Appointed Associate Director for Basic Research, Case Comprehensive Cancer Center

Ruth Keri, PhDAfter a national search, I am delighted to announce the appointment of Ruth Keri, PhD, to the position of Associate Director for Basic Research, Case Comprehensive Cancer Center. Dr. Keri is an associate professor in the departments of pharmacology, genetics and oncology at CWRU. She received her PhD in the department of pharmacology here in 1992, working at the time on identifying the regulatory mechanisms underlying pituitary gonadotropin hormone gene expression using novel transgenic mouse models. Her interest in the effects of reproductive hormones led to her long-standing interest in breast cancer, and a more recent interest in human breast cancer. She has done a remarkable job linking basic and animal model research to human disease, and in developing the key translational teams that are required for such complex research activities. She serves on a number of NIH and DOD scientific review panels, has been identified as a key investigator in breast cancer, and is recognized as a top educator in the department of pharmacology.

Recently, Dr. Keri's research activities have been to interrogate the role of HER2/c-neu/erbB2 in tumor progression and the impact of a variety of inhibitors on the signaling pathways activated by this receptor, to understand the role of FOXA1 in normal mammary ductal morphogenesis and breast tumor phenotypes, to understand the function of a Kruppel-like factor in epithelial to mesenchymal transition and metastasis, and to evaluate the role of LMO4 in breast-cancer proliferation.

In her position as associate director, Ruth will work with the Cancer Center leadership to develop the priorities and scientific direction of the Center, and will work with the leaders of all programs involved in basic laboratory investigation with an orientation towards promoting translational and disease-based research amongst investigator teams. Dr. Keri will be central to the development of a strategic plan for the Cancer Center, moving us into current preparations for our renewal application due in May of 2012.

Please feel free to contact Dr. Keri regarding any of these initiatives or about her own research. I am sure you will hear more from her soon as she begins to participate in program and scientific focus area meetings.

Stan Gerson, MD
Director, Case Comprehensive Cancer Center


Studies Link Missing Gene to Drug-Resistant Cancers - Mar 2, 2011
But Alex Almasan, a cancer biology researcher at the Cleveland Clinic who has studied FBW7, said the new studies give reason to be optimistic. In addition to elucidating a possible reason for the failure of current treatments, the studies present a ...


New Members

Please join us in welcoming the newest members of the Case CCC:

Stanley Hazen, PhD
Professor, Cell Biology 
Developmental Therapeutics Program

Steve Huang, MD, PhD
Assistant Professor, Nuclear Medicine
Cancer Imaging Program

Gary Landreth, PhD
Professor, Neurosciences
Developmental Therapeutics Program

Gordon McLennan, MD
Staff Physician, Diagnostic Radiology
Cancer Imaging Program

Vincent Tuohy, PhD
Professor, Immunology
Developmental Therapeutic Program


Case CCC Scientific Series

The next installment of the Case CCC Scientific Series is scheduled for Thursday, April 21 from 4-6:30 pm in Wolstein Auditorium (WRB 1-413). Drs. Anton Gorbachev, Neetu Gupta and Alex Huang will discuss the topic of Immunology. Presentations will be followed by a short receptions. All are encouraged to attend.

2nd Annual Department of Medicine Research Day

Department of Medicine faculty and trainees are invited to participate in the 2nd Annual Department of Medicine Research Day, Monday, May 16 from 12-5 pm in the Wolstein Research Building auditorium and lobby.

The mission of Research Day is twofold. First is to recognize and showcase the wide range of research in the Department by our young investigators at all levels of training. Second, is to provide an opportunity for departmental faculty to share ideas and knowledge and to stimulate discussion about opportunities for collaboration.

All Department of Medicine faculty and trainees are encouraged to attend this important event. In addition, young researchers (faculty within 5 years of appointment, fellows, residents and post-doctoral and graduate students) are invited to submit abstracts for poster presentation. Visit theevent webpage for details.

Case CCC Annual Scientific Retreat

The Case CCC Annual Scientific Retreat will be July 8-9 at Corporate College East. Details will be posted soon.


Uniting Against Lung Cancer

Uniting Against Lung Cancer is accepting applications for the2011 Legacy Program for Advances in Lung Cancer Research.In 2011, the program is prioritizing innovative, high risk/high reward research, with an aim towards jumpstarting new projects leading to improved treatments and a cure for lung cancer, including non-small cell and small cell lung cancer. Proposals do not require large amounts of preliminary data, but must have a clear hypothesis and research plan to be completed within the two year grant term. This funding is intended primarily as seed money for promising and potentially transformative new projects, rather than funding well-developed clinical projects that already receive considerable support. However, high risk/high reward add-on studies leveraging larger ongoing projects, or pre-existing data-sets, clinical samples, etc. are of interest. Investigators at all levels will be funded through the Legacy Program and are encouraged to apply.

Deadline: August 17


March 22

Featured Article: Fertility Still Possible for Many Male Cancer Survivors, Study Finds

U.S. Cancer Survivors Increase to Nearly 12 Million

Thyroid Cancer Risk Persists in People Exposed to I-131 Radiation as Children

Incidence Rate of Second Cancer in the Opposite Breast Has Declined in U.S.

Eribulin Improves Survival of Women with Metastatic Breast Cancer

Experimental Strategy May Overcome Resistance to Breast Cancer Drug

Devastation and Hope: An NCI Scientist's First-Hand Account of Japan's Resilience

In Depth
Colorectal Cancer Test Targets Cancer Stem Cells in Blood

Miniaturized Device Puts Nanotechnology to Work in Diagnosing Cancer

Featured Clinical Trial: Novel Combination Chemotherapy for Localized Ewing Sarcoma

FDA Update





**All events are open to anyone interested in attending

March 28

Pathology Research Seminar
Pamela Stanley, PhD
Professor, Cell Biology
Yeshiva University
Topic: Regulation of Notch Signaling by Glycans
12 pm WRB 1-413

Cancer Imaging Program (CIP) Microenvironment Focus Group "Mini Talk"
Speakers: Drs. Ann-Marie Broome, ZR Lu, and Horst von Recum
2 pm Wearn B37

SDIG Meeting
Mark Adams, PhD
Associate Professor, Genetics
Topic De Novo Assembly and Analysis of the Transcriptome of a Non-model Rodent Species
2:30 pm WRB 2-136

Physiology and Biophysics Seminar
Mark Snider, PhD
Associate Professor, Chemistry
College of Wooster
Topic: Structural and Mechanistic Studies of Proteins of Unknown Function
4 pm SOM E501

March 29

Cellular and Molecular Biology of Disease: A Symposium Series
Michael Clarke, MD
Professor, Medicine-Oncology
Associate Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine
Stanford University
Topic: Cancer Stem Cells- An Overview
10:30 am WRB 1-413

Cancer Biology Invited Speaker Seminar
Dean Bacich, PhD
Assistant Professor, Urology
University of Pittsburgh
Topic: PSMA and Dietary Folate Modulate Prostate Cancer
Denise O'Keefe, PhD
Assistant Professor, Urology
University of Pittsburgh
Topic: Dietary Folate and Epigenetic Regulation in the Prostate
11 am NC1-202 Cleveland Clinic

Immunology Seminar
Justine Tigno-Aranjuez, PhD
Postdoctoral Fellow, Pathology
Topic: Molecular Dissection of NOD2 Activation and Regulation: Old Players, New Targets
12 pm BRB 105

Special Seminar
Thomas Egelhoff, PhD
Professor, Cell Biology
CWRU/Cleveland Clinic
Topic: Myosin II motor proteins: Cytoskeletal Roles in Cancer Cell Migration and Skin Development
1 pm NE1-205

Cellular and Molecular Biology of Disease: A Symposium Series
Michael Clarke, MD
Professor, Medicine-Oncology
Associate Director, Stanford Institute for Stem Cell Biology and Regenerative Medicine
Stanford University
Topic: microRNA Regulation of Self-Renewal in Stem Cells and Cancer
4 pm WRB 1-413

March 30

Hematology and Oncology Division Research Conference
Henry Koon, MD
Assistant Professor, Medicine- Hem/Onc
Michelle Treasure, MD
Resident, Medicine
Meghan Zona, RN
Quality Center
Topic: Morbidity and Mortality Conference
8 am Lerner Tower B-151

March 31

13th Lerner Lecture
Patrick Brown, MD, PhD
Professor, Biochemistry
Stanford University
Topic: A Recurrent Gene Fusion in Serous Ovarian Cancer - the Dark Matter of the Cancer Genome?
4 pm Bunts Auditorium

April 1

Cancer Center Research in Progress Seminar canceled- AACR

Cancer Center Seminar Series canceled-AACR

Hematology/Oncology Fellows
Oana Paun, MD
Fellow, Div. of Hem/Onc
Topic: Trends in AML
8 am Wearn 137

Taussig Cancer Institute Grand Rounds
Gerold Bepler, MD
Associate Dean for Cancer Programs & Professor
Wayne State/Karmanos Cancer Institute
Topic: Molecular Markers for Therapeutic Decisions in Non-Small Cell Lung Cancer
8 am R3/002-003 Cleveland Clinic

Case CCC Calendar

LRI Calendar


Breast Cancer Detection and Management: Issues for 2011
May 20
Hilton Cleveland East

Case CCC Annual Scientific Retreat
July 8-9
Details to follow


4th Annual Biospecimen Research Network (BRN) Symposium: Advancing Cancer Research Through Biospecimen Science
March 28-29
Bethesda North Marriott Hotel & Conference Center in Bethesda, Maryland

Fourth Annual Translational to Clinical (T2C) Wound Care Conference
April 8-9
Ohio Union, Ohio State University, Columbus

Midwest Blood Club 9th Annual Symposium
April 21-22
Cincinnati Children's Hospital Medical Center

2011 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting
April 27-29
Omni Shoreham in Washington, DC

Cincinnati Cancer Symposium Series: 2011 Symposium on NF-κB, Cancer, Obesity, and Inflammation
May 1-4
Westin Hotel Cincinnati

4th International Symposium on Cancer Metastasis and the Lymphovascular System
May 12-14
New York City

Race for the Place
June 5
Beachwood Place Mall

International Society for Stem Cell Research (ISSCR) Annual Meeting
June 15-18
Toronto, Canada

Cancer Health Disparities Summit 2011
July 13-15
Bethesda North Marriott Hotel in Rockville, Maryland

8th International Conference of the Society for Integrative Oncology
November 10-12
InterContinental Hotel Cleveland


Multiple Myeloma Research Foundation 2011 Research Fellow Award Program
Deadline: March 29 

National CENter for ReGenerAtive Medicine UnderGraduate StudEnt (ENGAGE) Summer Program
Deadline: March 31

ACS Research Scholar Grants
Deadline: April 1

CTSC Quarterly Core Utilization Pilot Funding
CWRU, UH and MetroHealth investigators
Cleveland Clinic investigators should contact Charlotte Bhasinfor information
Deadline: April 1

Avon Foundation Breast Cancer Research Program
Cycle 2 LOI Deadline: May 6
Cycle 2 Full Proposal Deadline: July 5

Lustgarten Foundation Fall 2011: Basic Research Innovator Awards
Concept Proposal Deadline: September 14
Full Application Deadline: October 31

Translational Technology Concept Studies of Circulating Tumor and Endothelial Cells (CTC/CEC)
Deadline: Open

AACR Scholar-in-Training Awards - Other Conferences and Meetings
Deadline: Open

International Union Against Cancer (UICC) International Cancer Technology Transfer Fellowships
Application Deadline: Open

NCI Short-Term Scientist Exchange Program
Application Deadline: Open

James S. McDonnell Foundation Collaborative Activity Awards
Application Deadline: Open

NIH BULLETIN – Notices and Funding Opportunities

Re-Issuance of Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent T32) and Short-Term Institutional Research Training Grants (Parent T35) (NOT-OD-11-060)

Clarification, Institutional Clinical and Translational Science Award (U54), RFA-RM-10-020 (NOT-RM-11-012)

Research on Ethical Issues in Biomedical, Social and Behavioral Research (R01) (PA-11-180)

Research on Ethical Issues in Biomedical, Social, and Behavioral Research (R21) (PA-11-182)

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent T32) (PA-11-184)

Produced by:
Gillian Irwin Todd
11100 Euclid Avenue, Wearn 149
Cleveland, Ohio 44106-5065
216-844-8317 phone
216-844-7832 fax


If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades!

Send items to